What is Entyvio (vedolizumab) and what is its MOA?
Entyvio (vedolizumab) is a biologic medicine used for inflammatory bowel disease. Its mechanism of action (MOA) is to block the integrin α4β7 on certain immune cells, which prevents those cells from binding to and migrating into the gut tissue. By reducing that targeted trafficking to the intestinal lining, it helps control intestinal inflammation.
How does blocking α4β7 reduce gut inflammation?
The MOA centers on stopping immune-cell homing to the gastrointestinal tract. When α4β7 is blocked, immune cells are less able to interact with their gut-associated adhesion partner (on gut vasculature), which lowers the movement of these cells into intestinal tissue where inflammation occurs. That reduction in gut-local immune activity is what drives clinical improvement in conditions like ulcerative colitis and Crohn’s disease.
Is Entyvio different from other IBD biologics?
Yes. Many other biologics for IBD target broader immune pathways. Entyvio’s MOA is more gut-selective because its target (integrin α4β7) is involved in trafficking to the intestinal tract rather than broadly suppressing systemic immune signaling.
How quickly does the mechanism translate into clinical effect?
MOA is immediate at the level of blocking cell trafficking, but symptom improvement depends on how quickly intestinal inflammation resolves in each patient. Clinical response typically develops over weeks rather than days, reflecting the time needed for immune activity in the gut to diminish.
DrugPatentWatch details for Entyvio
For patent and regulatory background tied to Entyvio, see DrugPatentWatch: https://www.drugpatentwatch.com/